Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GVAX with SBRT and FOLFIRINOX in Resected Pancreatic Cancer
NCT01595321Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Oct 2012
- Primary completion
- Oct 2023
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of GVAX pancreatic cancer vaccine in pancreatic cancer (PC) (3 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Dose Limiting Toxicities at 8 weeks and Grade 3 or Higher Cy/GVAX-related Adverse Events at 116 months. Started Oct 2012; status: completed.
02
Drugs
GVAX pancreatic cancer vaccine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT01595321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01595321.